Meglucon

Metformin Hydrochloride, the active ingredient in Meglucon, is a biguanide presented as an oral tablet for oral use. It is used to improve blood glucose control in adults with type 2 diabetes mellitus.

GNH USA supplies Meglucon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meglucon (metformin) is employed in the management of disorders related to impaired glucose regulation. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - Prediabetes: reduces the risk of progression to overt diabetes. - Polycystic ovary syndrome: helps restore regular ovulatory cycles and improves insulin resistance.

Metformin is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools, especially during treatment initiation. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration in taste perception. - Weight loss: modest reduction in body weight. - Vitamin B12 deficiency: decreased absorption with long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: life‑threatening accumulation of lactate, especially in renal impairment. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Hypoglycemia: uncommon when used alone but possible with concomitant insulin or sulfonylureas.

Before initiating Meglucon, several safety considerations should be observed. - Renal function assessment: avoid use in severe renal impairment. - Hepatic function monitoring: contraindicated in active liver disease. - Lactic acidosis risk: discontinue before any radiographic contrast studies. - Elderly patients: start at lower dose and monitor tolerance. - Concomitant medications: review for drugs that may affect renal clearance. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformin may interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Iodinated contrast agents: increase risk of acute kidney injury and lactic acidosis. - Alcohol: potentiates lactic acidosis, especially with chronic intake. - Cimetidine: may raise metformin plasma concentrations.

Moderate Interactions (Monitor Closely): - Beta‑blockers: can mask hypoglycemia symptoms. - Diuretics and ACE inhibitors: may affect renal function and metformin clearance. - NSAIDs: can reduce renal perfusion, increasing metformin exposure.